| Primary Identifier | MGI:3852352 | Allele Type | Transgenic |
| Attribute String | Inducible, Recombinase | Gene | Et(icre/ERT2)10727Rdav |
| Strain of Origin | C57BL/6J | Induced With | tamoxifen |
| Is Recombinase | true | Is Wild Type | false |
| Project Collection | Neuroscience Blueprint cre |
| molecularNote | An enhancer trap transgenic approach was used to generate these mice. The hsyn-bgi-cre:ERT2-bGHpA transgene was designed with the human synapsin minimal promoter (hsyn) minimal promoter driving an icre-ERT2 fusion gene (a codon-improved cre recombinase sequence fused to a G400V/M543A/L544A triple mutation of the human estrogen receptor ligand binding domain). A beta globin intron separates the promoter from the cre gene and the bovine growth hormone polyadenylation signal follows the cre sequence. This transgene was injected into C57BL/6J embryos. Founder line 10727 was established on a C57BL/6J genetic background. |
